Gland Pharma Limited informed that the USFDA has indicated the closure of inspection.
The company stated in an exchange filing that following the pre-market inspection for medical devices covering the USFDA’s Quality System/Current Good manufacturing practice regulations at its Dundigal Facility at Hyderabad from August 22, 2022 to August 25, 2022, it has received the Establishment Inspection Report (EIR) from the Office of Product Evaluation and Quality Center for Devices and Radiological Health, USFDA.
This report indicates closure of the inspection conducted the company’s facility.
Following this development, Gland Pharma was trading at Rs1,575.15 apiece, against its previous close of Rs1,575.75 on NSE. The counter touched an intraday high and low of Rs1,598.80 and Rs1,566 respectively.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.